Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of serv...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

jaydilks Aug. 3 at 11:35 AM

$DNA People really haven’t discussed we have a new Chief Financial Officer that assumed the role in May after joining Ginkgo a year earlier from a long career at $CRL and with Deloitte. As soon as Steve took over for Mark Dmytruk, Ginkgo Bioworks hired Deloitte to be the new Auditor. One of the biggest complaints and maybe rightfully so, was the previous CFO would have this certain knack for taking perceived good news on the call and turning it into something that was fleeting success and a one-time event. The nerd in me realized he was just covering his butt for the future. The business part of me wanted to figuratively, slap him for opening his mouth and just take a win. So Thursday will be different. One could say it can’t be worse from a Theatrical point of view. Charles River Labs is a tough and Complex business. I could make a case that DNA is an infinitely easier gig just from the scale of operations.

1 · Reply

YouOnlyLiveTwice Jul. 30 at 11:12 PM

$CRL They had their run for a few days now back to their 3 year downtrends This space is very much out of favor. This could last another 3 years ONLY this changes is through consolidation otherwise lower

0 · Reply

ZacksResearch Jul. 30 at 1:31 PM

$CRL set for Q2 earnings — will it beat expectations again? 📈 CRL has an Earnings ESP of +0.11% and a Zacks Rank #3, indicating potential for a beat. Yet, challenges like NIH budget cuts and tariffs could pressure revenues and margins. Discover the full earnings preview here 👉 https://www.zacks.com/stock/news/2638082/charles-river-q2-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2638082-body-4658&ADID=SYND_STOCKTWITS_TWEET_2_2638082_BODY_4658

0 · Reply

ZacksResearch Jul. 30 at 12:03 PM

$CRL Q2 preview — is the setup bullish or bearish? 🧐 Investors are watching closely as Charles River prepares to report Q2 results — expectations and surprises could swing the stock. Full preview and setup breakdown here 👉 https://www.zacks.com/stock/news/2638082/charles-river-q2-earnings-preview-whats-in-store-for-the-stock?cid=sm-stocktwits-2-2638082-teaser-4651&ADID=SYND_STOCKTWITS_TWEET_2_2638082_TEASER_4651

0 · Reply

ccnau Jul. 24 at 1:47 PM

$CRL up, Chuck

0 · Reply

YouOnlyLiveTwice Jul. 21 at 7:42 PM

$CRL

0 · Reply

YouOnlyLiveTwice Jul. 18 at 4:46 PM

$CRL All these med device companies are in big trouble from a TA perspective as well as growth All value traps

1 · Reply

TegridyStocks Jul. 17 at 4:21 AM

$CRL alert set at $164.90

0 · Reply

ZacksResearch Jul. 16 at 1:25 PM

$CRL: Signs of stabilization, but macro risks loom ⚖️ 🔍 DSA segment shows promise with net book-to-bill rising above 1X for the first time in over two years. 🌍 Yet, currency woes and cautious biopharma spending pose ongoing challenges. See if $CRL can navigate these headwinds here 👉 https://www.zacks.com/stock/news/2585017/is-it-prudent-to-retain-charles-river-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2585017-body-1998&ADID=SYND_STOCKTWITS_TWEET_2_2585017_BODY_1998

0 · Reply

ZacksResearch Jul. 16 at 11:51 AM

$CRL showing strength — but is it enough to hold? Drug discovery and safety services are gaining momentum, but macro pressures and currency headwinds are putting a lid on growth. Full risk/reward breakdown here 👉 https://www.zacks.com/stock/news/2585017/is-it-prudent-to-retain-charles-river-stock-in-your-portfolio-now?cid=sm-stocktwits-2-2585017-teaser-1953&ADID=SYND_STOCKTWITS_TWEET_2_2585017_TEASER_1953

0 · Reply

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 20 days ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 7 weeks ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 2 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

May 28, 2025, 8:00 AM EDT - 2 months ago

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

May 13, 2025, 8:00 AM EDT - 2 months ago

Charles River Laboratories to Present at Bank of America Health Care Conference

May 10, 2025, 8:49 AM EDT - 3 months ago

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

May 7, 2025, 5:31 PM EDT - 3 months ago

S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments

May 7, 2025, 2:46 PM EDT - 3 months ago

Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript

May 7, 2025, 12:39 PM EDT - 3 months ago

Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization

May 7, 2025, 12:17 PM EDT - 3 months ago

Charles River Stock Is Having Its Best Day in 13 Years. A Board Shake-Up and Business Review Will Help.

May 7, 2025, 11:56 AM EDT - 3 months ago

Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More

DIS SMCI

May 7, 2025, 7:35 AM EDT - 3 months ago

Charles River to add new directors, review business in agreement with Elliott

May 7, 2025, 7:01 AM EDT - 3 months ago

Charles River Laboratories Announces First-Quarter 2025 Results

May 7, 2025, 7:00 AM EDT - 3 months ago

Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value

May 7, 2025, 6:08 AM EDT - 3 months ago

Exclusive: Charles River agrees with Elliott to add new directors, review business

Apr 29, 2025, 8:00 AM EDT - 3 months ago

Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort

Apr 22, 2025, 8:00 AM EDT - 3 months ago

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

Apr 15, 2025, 4:30 PM EDT - 3 months ago

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

Apr 11, 2025, 10:44 AM EDT - 4 months ago

What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?

CERT SLP

Mar 25, 2025, 8:00 AM EDT - 4 months ago

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

Mar 11, 2025, 8:00 AM EDT - 5 months ago

Charles River Laboratories to Present at Barclays Global Healthcare Conference

Mar 4, 2025, 4:05 AM EST - 5 months ago

FairJourney Biologics Acquires Charles River Laboratories South San Francisco Facility

Feb 25, 2025, 8:00 AM EST - 5 months ago

Charles River Announces Agreement with Singapore General Hospital

Feb 19, 2025, 4:58 PM EST - 5 months ago

Analyst Sees Charles River As Preclinical Leader But Maintains Neutral Stance

Feb 19, 2025, 3:03 PM EST - 5 months ago

Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 8:11 AM EST - 5 months ago

Charles River beats quarterly estimates on stable demand for drug development services

Feb 19, 2025, 7:00 AM EST - 5 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2024 Results and Provides 2025 Guidance

Feb 11, 2025, 8:00 AM EST - 6 months ago

Charles River and Deciphex Extend Global Partnership to Expand Digital Pathology Offering with Exclusive Image Management Solutions

Jan 28, 2025, 4:30 PM EST - 6 months ago

Charles River Laboratories Schedules Fourth-Quarter 2024 Earnings and 2025 Guidance Release and Conference Call

Jan 21, 2025, 8:00 AM EST - 6 months ago

Charles River Expands Apollo™ Ecosystem, Offering Bespoke Client Experiences

Jan 16, 2025, 8:00 AM EST - 7 months ago

Charles River and Akron Bio Announce Collaboration to Enhance Operations with Integration of CGMP Materials into Cell Therapy Platform

Jan 13, 2025, 8:00 AM EST - 7 months ago

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Jan 7, 2025, 8:00 AM EST - 7 months ago

Deciphex Secures $32.3M Series C to Address Global Pathology Shortage

Dec 20, 2024, 7:51 AM EST - 8 months ago

Tax-related selling is hitting these 7 stocks — but their loss could be your gain

AVNW CVS DLHC FL VAL

Dec 5, 2024, 8:00 AM EST - 8 months ago

Charles River Introduces Global Biotech Incubator Program

Dec 2, 2024, 8:00 AM EST - 8 months ago

Charles River Laboratories to Present at Evercore ISI Investor Conference

Nov 11, 2024, 8:00 AM EST - 9 months ago

Charles River Laboratories to Present at UBS and Jefferies Conferences

Nov 6, 2024, 6:51 PM EST - 9 months ago

Charles River Laboratories International, Inc. (CRL) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 8:30 AM EST - 9 months ago

Charles River Laboratories raises annual profit forecast on stabilizing biotech demand

Nov 6, 2024, 7:00 AM EST - 9 months ago

Charles River Laboratories Announces Third-Quarter 2024 Results

Oct 17, 2024, 8:00 AM EDT - 10 months ago

Charles River Launches New Retrogenix® Non-Human Protein Library

Oct 16, 2024, 4:30 PM EDT - 10 months ago

Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call

Oct 8, 2024, 11:26 AM EDT - 10 months ago

Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform

Oct 3, 2024, 8:00 AM EDT - 10 months ago

Charles River Provides Translational Expertise at Neuroscience 2024

Oct 2, 2024, 8:00 AM EDT - 10 months ago

Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease

Sep 19, 2024, 6:00 AM EDT - 11 months ago

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Sep 18, 2024, 8:30 AM EDT - 11 months ago

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing

Sep 17, 2024, 8:00 AM EDT - 11 months ago

Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience

jaydilks Aug. 3 at 11:35 AM

1 · Reply

YouOnlyLiveTwice Jul. 30 at 11:12 PM

0 · Reply

ZacksResearch Jul. 30 at 1:31 PM

0 · Reply

ZacksResearch Jul. 30 at 12:03 PM

0 · Reply

ccnau Jul. 24 at 1:47 PM

$CRL up, Chuck

0 · Reply

YouOnlyLiveTwice Jul. 21 at 7:42 PM

$CRL

0 · Reply

YouOnlyLiveTwice Jul. 18 at 4:46 PM

$CRL All these med device companies are in big trouble from a TA perspective as well as growth All value traps

1 · Reply

TegridyStocks Jul. 17 at 4:21 AM

$CRL alert set at $164.90

0 · Reply

ZacksResearch Jul. 16 at 1:25 PM

0 · Reply

ZacksResearch Jul. 16 at 11:51 AM

0 · Reply

VENIVICI Jul. 15 at 7:44 PM

Wait, was Charles River Laboratories $CRL the unnamed third-party manufacturer involved in $ATRA ’s Complete Response Letter back in January?

0 · Reply

JarvisFlow Jul. 9 at 1:00 PM

Evercore ISI Group has adjusted their stance on Charles River ( $CRL ), setting the rating to Outperform with a target price of 170 → 180.

0 · Reply

JarvisFlow Jul. 9 at 12:30 PM

Citigroup updates rating for Charles River ( $CRL ) to Buy, target set at 150 → 200.

0 · Reply

JarvisFlow Jun. 25 at 10:00 AM

Barclays has updated their rating for Charles River ( $CRL ) to Equal-Weight with a price target of 205.

0 · Reply

MomentumWins Jun. 20 at 5:47 PM

$CRL 250 breach needs some mojo… it got it now

0 · Reply

JarvisFlow Jun. 18 at 10:00 AM

Redburn Atlantic updates rating for Charles River ( $CRL ) to Neutral, target set at 171 → 188.

0 · Reply

swingingtech Jun. 17 at 7:13 PM

$CRL $ALGN $ENPH $FSLR https://wallstreetwaves.com/tuesdays-market-weakness-declines-in-healthcare-technology-and-communications-sectors/

0 · Reply

JarvisFlow Jun. 13 at 2:53 PM

Morgan Stanley updates rating for Charles River ( $CRL ) to Equal-Weight, target set at 225 → 220.

0 · Reply

FinJay Jun. 6 at 2:11 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

ZacksResearch Jun. 2 at 2:55 PM

$CRL extends its Huntington's partnership with CHDI Foundation — is sentiment shifting? 🤔 Following the news, shares of Charles River rose 1.1% as the collaboration is set to reach its 20th anniversary in 2025, fueling market optimism. CRL's earnings yield of 7.09% also shines against the industry’s 4.02% yield. See why this extension could boost CRL's outlook 👉 https://www.zacks.com/commentary/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-body&ADID=SYND_STOCKTWITS_TWEET_2_2480029_BODY

0 · Reply

ZacksResearch Jun. 2 at 11:15 AM

$CRL expands global reach with extended CHDI deal! The extended partnership with the CHDI Foundation promises deeper integration and global flexibility in Huntington's drug discovery. See why this could lift the stock 👉 https://www.zacks.com/stock/news/2480029/charles-river-stock-may-gain-from-extended-chdi-research-deal-on-hd?cid=sm-stocktwits-2-2480029-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2480029_TEASER

0 · Reply

FinJay May. 26 at 3:48 AM

$CRL https://youtu.be/yQKMLlDzMzM

0 · Reply

Market Cap	8.20B
Revenue (ttm)	4.05B
Net Income (ttm)	22.20M
EPS (ttm)	N/A
PE Ratio	16.33
Forward PE	17.63
Profit Margin	0.55%
Debt to Equity Ratio	0.78

Volume	623,700
Avg Vol	822,586
Day's Range	N/A - N/A
Shares Out	49.12M
Stochastic %K	27%
Beta	1.48
Analysts	Sell
Price Target	$164.00